目的 探讨珠贝定喘丸对慢性支气管炎患者临床症状和血清及诱导痰炎症介质水平的影响.方法 收集浙江省立同德医院呼吸科2016年1月～2017年1月收治的慢性支气管炎患者80例,随机分为对照组和观察组,各40例,对照组予对症支持治疗,观察组在对照组的基础上加用珠贝定喘丸治疗,测量2组患者治疗前后血清及诱导痰炎症介质水平的变化,观察2组患者临床疗效.结果 观察组治疗后血清及诱导痰白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)均明显低于对照组(P<0.05);观察组治疗后有效率(95.0％)明显高于对照组(82.5％)(P<0.05).结论 珠贝定喘丸能有效缓解慢性支气管炎患者临床症状,其药理机制与降低血清及气道局部炎症介质水平有关.%Objective To investigate the effect of Zhubei Dingchuan pill on clinical symptoms and inflammatory mediators in serum and induced sputum of patients with chronic bronchitis. Methods 80 cases of patients with chronic bronchitis treated in the Department of Respiration in our hospital from January 2016 to January 2017 were selected and were randomly divided into the control group and the observation group, with 40 cases in each group. The control group was given symptomatic support treatment and the observation group was additionally given Zhubei Dingchuan pills on the basis of the control group. The changes of inflammatory mediators levels in serum and induced sputum were measured before and after treatment between the two groups, and the clinical efficacy was observed in the two groups. Results After treatment, the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high-sensitivity C reactive protein (hs-CRP) in serum or induced sputum in the observation group were significantly lower than those in the control group (P<0.05). The effective rate of treatment in the observation group was significantly higher than that in the control group (95.0％ vs. 82.5％) (P<0.05). Conclusion Zhubei Dingchuan pill can effectively relieve the clinical symptoms in patients with chronic bronchitis, and its pharmacological mechanism is related to the decrease of levels serum and airway inflammatory mediators.
展开▼
